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Abstract
Background: As the amount of publicly available biomedical data increases, discovering hidden knowledge from
biomedical data (i.e., Undiscovered Public Knowledge (UPK) proposed by Swanson) became an important research
topic in the biological literature mining field. Drug indication inference, or drug repositioning, is one of famous
UPK tasks, which infers alternative indications for approved drugs. Many previous studies tried to find novel
candidate indications of existing drugs, but these works have following limitations: 1) models are not fully
automated which required manual modulations to desired tasks, 2) are not able to cover various biomedical
entities, and 3) have inference limitations that those works could infer only pre-defined cases using limited
patterns. To overcome these problems, we suggest a new drug indication inference model.
Methods: In this paper, we adopted the Typed Network Motif Comparison Algorithm (TNMCA) to infer novel drug
indications using topology of given network. Typed Network Motifs (TNM) are network motifs, which store types of
data, instead of values of data. TNMCA is a powerful inference algorithm for multi-level biomedical interaction data
as TNMs depend on the different types of entities and relations. We utilized a new normalized scoring function as
well as network exclusion to improve the inference results. To validate our method, we applied TNMCA to a public
database, Comparative Toxicogenomics Database (CTD).
Results: The results show that enhanced TNMCA was able to infer meaningful indications with high performance
(AUC = 0.801, 0.829) compared to the ABC model (AUC = 0.7050) and previous TNMCA model (AUC = 0.5679,
0.7469). The literature analysis also shows that TNMCA inferred meaningful results.
Conclusions: We proposed and enhanced a novel drug indication inference model by incorporating topological
patterns of given network. By utilizing inference models from the topological patterns, we were able to improve
inference power in drug indication inferences.
Background
In 1986, Swanson proposed Undiscovered Public Knowl-
edge (UPK) as an undiscovered knowledge which can be
inferred by considering two (or more) complementary
public relations [1]. UPK model is also said to be ABC
model, because it implies that, even though there is no
interaction between the entity A and the entity C, if
there are associations between A and B, and between B
and C, a new relation between A and C can be inferred.
(See Figure 1.) Using the method, Swanson inferred sev-
eral interactions. One of the inference results was the
interaction between ‘Fish oil’ and ‘Raynaud’s Disease’.
After three years, this hypothesis was proved by DiGia-
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There were many attempts to improve UPK model.
Hristovski, et al. [3] utilized the MeSH descriptors as
features, and searched co-occurrence of the words. Pratt
and Yestisgen-Yildiz [4] used Unified Medical Language
System (UMLS) concepts as features, and searched only
the titles as a starting concept. To reduce the number of
concepts, they categorized the terms. Lee, et al. [5] uti-
lized context terms to achieve better precision.
Drug indication inference, also known as drug reposi-
tioning, is one of famous UPK tasks. It infers alternative
indications for approved drugs. By using conventional
pharmacology techniques, developing a new drug requires
high costs both in time and money. [6] Aided by the
growth of computation power, repositioning approved
drugs to new indications has decreased development costs
of drugs.
Previous works of drug indication inference utilized
various biological data sources to infer novel drug indica-
tions. Lamb, et al. [7] used the Connectivity Map (CMap)
which ranks drug response gene expression profiles.
Chiang and Butte [8] proposed the Guilt by Association
(GBA) which suggests new indications by assuming that
if two diseases have same indication, another drug which
treats only one of them could treat the other. Gottlieb, et
al. [9] proposed utilized drug-drug and disease-disease
similarity measures in predicting drug indications.
These previous studies had several limitations. First,
most of them are not fully automated, and required man-
ual operations. Because of the amount of biomedical data
is large, automation is critical. Second, the previous works
were not performed in biomedical domains. It is necessary
to consider the characteristics of the data. Since biomedi-
cal data covers from molecular level entities to phenotypic
level entities, the information model should account for
various types. Third, most of the methods make inference
based on stereotypical inference models, which are
extended from Swanson’s ABC model. ABC model is
based on transitive inference, and it is difficult for biome-
dical data inference, because of the variety of entities and
relations.
To overcome these problems, we proposed Typed
Network Motif Comparison Algorithm (TNMCA). [10]
TNMCA is a method for drug repositioning from a large
amount of multi-level biomedical interaction networks by
employing typed network motif (TNM). Network motif is
introduced by Milo, et al. [11] as a pattern of connectivity
that occurs significantly more frequently than expected.
We evolved the concept into TNM which is more adapta-
ble to multi-type interaction networks. Whereas ordinary
network motif is based on the topological connectivity,
TNM considers types of nodes as well as edges.
Three inference models are represented in Figure 2. The
leftmost model is based on the pattern composed of drug,
gene, and disease. The middle model is based on the pat-
tern composed of drug, pathway, and disease. The right-
most model is based on the pattern composed of drug,
gene, pathway, and disease. If all three patterns are fre-
quently occurred in the network, and if we integrate the
inferred results from them, we can make a reliable and
novel inference. These frequent patterns are TNMs in our
Figure 1 Swanson’s UPK model. Swanson proposed the UPK model to discover the implicit relations among biological entities. The figure
shows how Swanson inferred relationship between fish oil and Raynaud disease.
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research, and we proposed a method to extract the TNMs
from the given network automatically. After extracting
TNMs, we applied them to make novel inferences.
TNMCA provides several advantages over previous
methods. TNMCA extracts TNM sets using the given
data itself, so that it would not require any manual opera-
tion. Previous researches utilize ABC model-based transi-
tive inferences. On the other hand, TNMCA is not
limited to the transitive inferences, and is possible for the
inference using generalized topological patterns. Also,
TNMCA is able to infer not only interactions but also
types of the interactions.
We applied two modifications to improve TNMCA.
First, we enhanced scoring function of TNMCA to over-
come normalization problems. Previous algorithm suf-
fered with normalization problems that the result scores
were not normalized on the size of given network and on
the size of inference patterns. By limiting the score range,
and modifying the summating operations, we could
improve scoring function of TNMCA. Second, we limited
training network to the network of associated diseases of
the target disease. We filtered out unrelated diseases by
disease hierarchy in Medical Subject Headings (MeSH)
[12]. The diseases in the same disease hierarchy with the
target disease were utilized as training set. By adopting
these two improvements, we could obtain better results.
We applied enhanced TNMCA, to the publicly avail-
able database, Comparative Toxicogenomics Database
(CTD) [13], to validate our method. We validated our
method by comparing inference results with previous
TNMCA, and ABC-based model. We used a scoring
function, which depends on the frequency ratio of refer-
enced patterns, to rank TNMCA results. The results
show that enhanced TNMCA was able to infer meaning-
ful indications with high performance compared to the
ABC model and previous TNMCA model. Moreover, we
confirmed that high-scored results of TNMCA results
are reported in the biomedical literature. These results
imply that TNMCA can make novel inferences in biome-
dical fields.
The rest of the paper is organized in the following order.
Methods section introduces our TNMCA technique and
Figure 2 An example of inference models. An example with three inference models. This shows necessity of TNMCA.
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the descriptions of the experiments. Result section reports
on the experiment results. Conclusion section concludes
the paper.
Methods
Inference model of TNMCA
Entities of biomedical data cover broad levels from the
molecular level such as DNA or chemical, to the phenoty-
pic level such as symptom or disease. Discovering the rela-
tions between different levels becomes important because
they can connect various data, and generate novel infor-
mation from the merged network. A few previous studies
proposed specific information models to store these var-
ious types of data. Ijaz, et al. [14] defined a specific frame
of entities as an information model. In this way, they
could store only the targeted information. Due to its
inflexibility of the model, if different types of data are
included, the information model could not handle them
directly, but needed manual alteration. Therefore, defining
appropriate information models is one of the challenging,
important issues in handling biomedical data.
We proposed and applied TNMCA to various biomedi-
cal data by using the TNM to build an inference model.
(See Figure 2.) For a given graph G = (V, E), where V =
{(v1, vt1), (v2, vt2), ..., (vn, vtn)} is the set of vertices with
their types in G, E={(e1, et1), (e2, et2), ..., (em, etm)| ei⊆{{(vj,
vtj), (vk, vtk)}| (vj, vtj)⊆V, (vk, vtk)⊆V and (vj, vtj)≠(vk, vtk)}}
is the set of edges with their types in G, we define the
typed network motif TNM⊆{(V’, E’)}, where V’⊆{vt1, vt2,
..., vtn}, E’={(e’1, et1), (e’2, et2), ..., (e’m, etm) | e’i⊆{{vtj, vtk} |
vtj⊆V’, vtk⊆V’}}, V’ is connected, count(V’)>2, degree(vti)
>1|vti⊆V’. We defined the TNM as a connected sub-graph
which contains more than two node types with degree lar-
ger than one, and their connecting edges (edge types are
optional). Both nodes and edges contain the types of their
original values (instead of the value itself). We defined the
TNM as connected, because unconnected biological con-
cepts mean unrelated information. We set the minimum
number of nodes to three because a two-node sub-graph
merely represents a relation not a pattern. The minimum
degree of nodes is limited to two because we cannot infer
relations from one-degree nodes.
The main objective of the TNM model is to find fre-
quent network patterns from the given network. To this
end, we proposed a concept, TNM, which was evolved
from the ordinary network motif. The ordinary network
motif is based on topology of given network. In contrast,
the TNM utilized the types of nodes and edges, so that it
could be applied to multi-level biological networks.
TNM nodes and edges contain entity types instead of
values. Using entity types instead of values gives novelty to
the inference model. Value-based models are limited to
make inferences using sub-networks with same values. In
contrast, the TNM model can be applied to sub-networks
with different values if the sub-networks have same type
topologies.
In Figure 3(A), which represents an example relational
network, nodes contain their values (such as TP53, P53,
E6, Pifithrin-alpha, and Cancer), but in Figure 3(B),
which shows the network’s possible three-node TNMs,
nodes contain their types (such as DNA, protein, chemi-
cal, and disease) only.
The TNM is a flexible information model that can be
applied to various types of information. The TNM does
not require any manual operation coupled with data. If
the model is to be applied to different data, all it takes is
to adjust the composing types of entities and relations.
Using the TNM as an information model of TNMCA
made the method to be applicable to various biomedical
data.
TNMCA architecture
Figure 4 shows the overall workflow of TNMCA.
TNMCA consists of four major modules; Network Gen-
erator, TNM Extractor, Indication Inference, and Statis-
tical Analysis modules.
Network generator constructs a backbone multi-type
interaction network by integrating interaction information
from CTD database[13]. During construction, non-drug
chemicals are excluded by referencing DrugBank database
[15], and unrelated diseases of target disease are excluded
by referencing MeSH disease hierarchy [12]. (See Experi-
ment section for precise description of the database.) In
validation, we set our task to find drugs for ‘Type 2 Dia-
betes Mellitus (T2DM)’. Therefore, during generating the
multi-type interaction network, we excluded chemical-dis-
ease interactions which include T2DM. We separated
them as an answer indication set, and compared it with
the inferred results.
TNM extractor extracts TNM from the backbone multi-
type interaction network. The extractor detects every
TNMs existing in the network. It checks every possible
connected k-node sub-graphs, and transforms them into
TNM. The TNMs and their frequencies in the network
are stored as the TNM set. The frequency is used as a sig-
nificance measure of each pattern. If a TNM has high fre-
quency, then it can infer confident knowledge.
Indication inference is performed by identifying new
indication candidates from the multi-type interaction net-
work using the extracted TNM set as inference models.
We search similarities between the extracted TNMs and
every possible connected sub-graph of the network. If all
of the parts of a sub-graph except one relation are
matched with one pattern of the TNM set, we can infer
the relation as new knowledge. To rank drug indication
candidates, every drug indication candidates are scored.
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Figure 3 Concept description of TNM. (A) An example relational network (relation value not indicated) and (B) its possible four-node TNMs.
TNMs use only types of nodes and types of relations (not their values).
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The TNM is scored by calculating proportion of the fre-













where i represents an index of TNMs, and j represents
an index of indications. As the score of TNMs are defined
as proportion of the frequency of the TNM, the range of
Figure 4 Overall workflow of TNMCA. TNMCA consists of four modules; Network Generator, TNM Extractor, Indication Inference and Statistical Analysis.
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the score is limited from 0 to 1. For example, if a drug
indication candidate is inferred from 20% frequent pattern
and 50% frequent pattern, then, the score of the drug indi-
cation candidate is
Score = 1− (1− 0.2) • (1− 0.5) = 0.6.
By using the equation, the indications always have big-
ger scores than the scores of every referenced TNMs. If
two or more indications have same scores, the indica-
tion which has higher frequency of referenced patterns
will go to higher rank. After scoring, the drug indication
inference system removes unimportant drug indication
candidates depending on the score of them with an
appropriate score threshold.
Statistical analysis is performed by comparing inferred
candidate indications with the answer indication set. By
drawing receiver operating characteristic (ROC) curve
based on the inference score, we could calculate area
under curve (AUC) value of ROC curve for the inference
results. ROC curve is created by plotting true positive rate
(TPR) on false positive rate (FPR) at various thresholds of
the score. The AUC value of ROC curve represents how
positive results are ranked higher than negative results.
Inference model generation/application
Our target is a multi-typed interaction network. (See
Figure 5(A).) A shape of each node illustrates the type
of each node. An edge between two nodes means those
two nodes have a specific relation. (In this example,
values and types of edges are not indicated.)
A frequent TNM in the network is treated as an impor-
tant one to represent a reasonable logic in the network.
(See Figure 5(B), and 5(C).) We utilized the TNMs as our
inference models to make inferences. Frequent patterns
are different for each network. TNMCA searches and
records these patterns with their frequency.
If there is a sub-network, which is similar with the fre-
quent pattern, we infer a new candidate relation from the
difference. (See Figure 5(D).) If there is a frequent pattern
in a specific network, it means there is a higher probability
for the network to have same patterns. Therefore, if there
is a sub-network similar with the pattern, we can infer
probable relations from it.
With the Swanson’s model, suppose that the rectangular
node is a chemical, the pentagonal node is a physical phe-
nomenon, and the circle node is a disease. Swanson’s
assumption was that if a specific chemical affects a specific
physical phenomenon, and the phenomenon affects a spe-
cific disease, then the chemical could affect the disease.
This assumption is applied to the frequent TNMs in the
network.
The Swanson’s model could define appropriate logics for
different networks. However, it requires filtering the
concepts or relations, and it may also need to define a new
transitive rule for complex networks. On the other hand,
TNMCA searches frequent patterns for each network to
discover appropriate patterns for each network. Since
these patterns are embedded in the given data sets, unlike
the Swanson’s model, it does not need any optional logic
definition.
Experiments
We used Comparative Toxicogenomics Database (CTD,
http://ctdbase.org/) as a database for generating a back-
bone multi-type interaction network[13]. CTD contains
manually curated and inferred interaction data among
diseases, chemicals, genes, and pathways. We used these
four biological entities as the types of nodes, and their
interaction types as the types of edges (if available). We
excluded GO entity, because CTD provides only chemi-
cal-GO associations and no other associations with GO.
Currently, CTD contains 560,956 chemical-gene associa-
tions, 9,919,586 gene-disease associations (22,446 curated
and 9,897,140 inferred), 1,015,365 chemical-disease asso-
ciations (175,272 curated and 840,093 inferred), 201,288
chemical-pathway associations, 43,970 disease-pathway
associations, and 62,254 gene-pathway associations.
Using disease hierarchy from the Medical Subject
Headings (MeSH, http://www.nlm.nih.gov/mesh/) data-
base, we can discriminate unrelated diseases of the
target disease from backbone network. MeSH is a hier-
archical vocabulary containing 26,853 descriptors.
We referenced the DrugBank (DrugBank, http://www.
drugbank.ca/) database to filter out non-drug chemicals
from the backbone interaction network [15]. DrugBank
offers 6,711 drug information with their targets. To
eliminate redundant interactions which include non-
drug chemicals from CTD database, we selected chemi-
cal interactions which have chemicals registered in
DrugBank.
We performed our evaluation by comparing our
enhanced TNMCA model with the previous TNMCA
model and basic ABC model. CTD database contained
25 drugs which have T2DM as their indications. The
indications were removed from input data, and both
model needed to find them from rest of input data.
ABC model inferred the results by connecting drug-gene
and gene-disease interactions or drug-pathway and path-
way-disease interactions. If a drug is connected to the
‘T2DM’ through any gene or pathway, the drug becomes
an inferred indication of ‘T2DM’. The counts of the
inferred indications were assigned as their scores.
Both TNMCA models extracted 3-node and 4-node
TNMs from the backbone network.
After we get results from all models, we compared
them with the answer set (25 indications of T2DM).
Because ABC model cannot infer interaction types, we
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Figure 5 Examples to explain inference model generation and application of TNMCA. (A) An example multi-typed relational network
(relation value not indicated). (B) A frequent TNM of the network is colored. (C) Generated inference model from the frequent TNM of the
network. (D) An inference of a new relation (dotted edge).
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rated the result correct if there is the result interaction in
the answer set. (Regardless of interaction types) On the
other hand, for TNMCA models, the result interactions
should match their types also. We calculated AUC values
of the ROC curves of the results.
Results
TNM results
We found unique 292 3-node TNMs, and 2,195 4-node
TNMs in the network. The 4-node TNM which has the
highest frequency is represented in Figure 6. As only
gene-disease, drug-disease, and drug-gene interactions
have interaction types, rest interaction types are not
represented in Figure 6. We can find that the top-rated
TNM does not have interaction between gene and drug.
This indicates that many drugs for a certain disease have
interaction with disease-related pathways, not disease-
related genes, which supports the claim of Pujol, et al.
[16] that pathway is more important than single protein
in multifactorial diseases.
Inference results
Figure 7 shows the result of our experiments. The graph
shows ROC curves of ABC model results, previous 3-node
TNMCA model results, previous 4-node TNMCA model
results, enhanced 3-node TNMCA model results, and
enhanced 4-node TNMCA model results respectively
according to their AUC values. The AUC values of ABC
model, previous 3-node TNMCA model, previous 4-node
TNMCA model, enhanced 3-node TNMCA model, and
enhanced 4-node TNMCA model are 0.7050, 0.5679,
0.7469, 0.801, and 0.829, respectively. We can find that our
enhanced model improved the AUC results in both 3-node
TNMCA model and 4-node TNMCA model. Previous
3-node TNMCA model had lower AUC value than ABC
model, but enhanced 3-node TNMCA model resulted
higher AUC value, in contrast. We should consider that
TNMCA model needed to match interaction types also,
whereas ABC model required the existence of the interac-
tion only. As inference power of TNMCA increases in pro-
portion to size k, the AUC results of them are proper. It is
Figure 6 The most frequent 4-node TNM. The 4-node TNM which has the highest frequency.
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outstanding that enhanced TNM showed higher AUC
value, even though it needed to match interaction types.
This supports the inference power of TNMCA.
It would be better if we could have experiments with lar-
ger k values (larger than 4) of TNM, because many novel
inferences will be performed using large k values. The
AUC values also support this claim because AUC value of
4-node TNMCA results was higher than that of 3-node
TNMCA results. Unfortunately, the processing time
increases exponentially by k. If we set k as 5, it took
several months to be performed, so we could not analyse
it properly in the time of submitting this paper.
Literature analysis
We conducted a literature review on the top 10 high-
est score results of enhanced 4-node TNMCA model.
(See Table 1.) The table shows related literatures for
the top 10 highest scored indications of ‘T2DM’ from
enhanced 4-node TNMCA model. We searched evi-
dences of interaction between the top 10 drugs and
Figure 7 Result of the experiments. ROC curves of five models are plotted with their AUC value. ABC represents basic ABC model. 3node and
4node represents previous TNMCA models. 3node+ and 4node+ represents enhanced TNMCA models.
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‘T2DM’. ‘Cyclosporine’ is duplicated, because there
were two inferences with different interaction types.
We were able to find evidences for 7 of 10 results
from literature. According to the results, high-scored
inferred relations from TNMCA have high reliability.
The rest of results, ‘Azacitidine’, ‘Tretinoin’, and ‘Dau-
norubicin’ can be treated as newly inferred indications
of ‘T2DM’.
Conclusions
Studies on drug repositioning have recently been rigor-
ously carried out, and it is a difficult challenge to infer
novel drug indications from a large amount of multi-level
biomedical interaction networks. We proposed a novel
automated inference method for various types of biome-
dical data. The method exports typed network motifs of
data, and infers novel hypotheses by comparing the
exported typed network motifs with the sub-graph of
data. The method was applied to CTD database, and it
achieved the outstanding performance.
The contribution of this paper is two-fold: 1) We devel-
oped a pattern finding model which can extract more
generalized patterns than ABC model to solve UPK pro-
blems. Most UPK models are depending on ABC pat-
terns or extension of ABC patterns. We propose more
generalized patterns to make novel inferences. 2) We
proposed an inference method which could infer interac-
tions as well as their interaction types whereas ABC
model could infer only the existence of interactions
between two entities.
As a follow-up study, we plan to apply TNMCA to more
complex database. CTD contained only 4 types of entities
and a few types of interactions. As TNMCA is dependent
on the network topology and their types, applying it to
complex database will make outperforming results.
Currently, a complex database is not available. Therefore
we plan to integrate several biomedical databases and elec-
tric health records to construct complex multi-type inter-
action network for TNMCA.
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Table 1 Literature analysis result.
Rank Chemical Name CasRN Literature Title
1 Cyclosporine 59865-13-3 The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with
diabetes mellitus. [17]
2 Heparin 9005-49-6 Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin. [18]
3 Cholecalciferol 67-97-0 Effect of cholecalciferol supplementation on blood glucose in an experimental model of type 2 diabetes
mellitus in spontaneously hypertensive rats and Wistar rats. [19]
4 Azacitidine 320-67-2 Newly inferred indication.
5 Cysteine 52-90-4 Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. [20]
6 Chenodeoxycholic
Acid
474-25-9 In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs):
chenodeoxycholic acid selectively inhibits 11beta-HSD-I. [21]
7 Diethylstilbestrol 56-53-1 The effect of diethylstilbestrol upon alloxan diabetes in the male rat. [22]
8 Tretinoin 302-79-4 Newly inferred indication.
9 Daunorubicin 20830-81-3 Newly inferred indication.
10 Ursodeoxycholic
Acid
128-13-2 Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2
Diabetes. [23]
Related literatures for the top 10 highest scored indications of ‘T2DM’ from enhanced4-node TNMCA model. Cycloporine [17], Heparin [18], Cholecalciferol [19],
Cycteine [20], Chenodeoxycholic Acid [21], Diethylstilbestrol [22], and Ursodeoxycholic Acid [23] were reported to have interactions with ‘T2DM’.
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